Press Releases COMPASS Pathways plc

Equities

CMPS

US20451W1018

Real-time Estimate Cboe BZX Other stock markets 01:53:46 2024-06-06 pm EDT			5-day change	1st Jan Change
7.1 ^USD	-4.95%		-4.86%	-19.32%

Jun. 05	Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating	MT
Jun. 04	FDA panel to review psychedelic drug MDMA for first time	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

COMPASS Pathways : 2024 AGM Voting Results	May. 13	PU
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights	May. 08	GL
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder	May. 08	GL
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment	May. 02	GL
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression	Apr. 29	GL
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors	Mar. 28	GL
COMPASS Pathways : Presentation – March 2024	Mar. 04	PU
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights	Feb. 29	GL
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved	Jan. 16	GL
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved	Jan. 16	AQ
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement	Jan. 05	GL
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement	Jan. 05	AQ
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder	Dec. 19	GL
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder	Dec. 19	AQ
Compass Pathways appoints Teri Loxam as Chief Financial Officer	Dec. 07	GL
Compass Pathways appoints Teri Loxam as Chief Financial Officer	Dec. 07	AQ
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry	Dec. 06	GL
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center	Nov. 15	GL
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights	Nov. 02	GL
COMPASS Pathways announces CFO transition	23-10-26	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases COMPASS Pathways plc

Equities

CMPS

US20451W1018

Press Releases

Filters